Evidence map›Paper›PMID 40175465›Full record

ArticleScientific reports2025

Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer.

Haruo Miyata, Hajime Shigeto, Tomoatsu Ikeya, Tadashi Ashizawa, Akira Iizuka, Yasufumi Kikuchi, Chie Maeda, Akari Kanematsu, Kazue Yamashita, Kenichi Urakami and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Haruo Miyata *Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Hajime Shigeto *Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Kagawa, Japan.
Tomoatsu IkeyaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Tadashi AshizawaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Akira IizukaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Yasufumi KikuchiImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Chie MaedaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Akari KanematsuImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Kazue YamashitaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Kenichi UrakamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yuji ShimodaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi OhshimaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuhisa OhdeDivision of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Mitsuhiro IsakaDivision of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Takashi SuginoDivision of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Koji MuramatsuDivision of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Hirotsugu KenmotsuDivision of Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Toshiaki TakahashiDivision of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Ken YamaguchiOffice of the President Emeritus, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Mizuki KitamatsuDepartment of Applied Chemistry, Kindai University, Osaka, Japan.
Shohei YamamuraHealth and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Kagawa, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. y.akiyama@scchr.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quickly identifying driver gene mutations in solid cancers is important. However, next-generation sequencing (NGS)-based mutation detection methods are time-consuming and expensive. Peptide nucleic acid (PNA) probe-based mutant mRNA detection systems are quick and inexpensive. We previously demonstrated that epidermal growth factor receptor (EGFR)-mutations were efficiently visualized in formalin-fixed paraffin-embedded (FFPE) specimens from transplanted non-small cell lung cancer (NSCLC) tumors using an EGFR mutation-specific PNA:DNA probe. Herein, the efficiency of PNA:DNA probes in detecting EGFR-mutations in FFPE specimens from patients with NSCLC and the colocalization of EGFR-mutations with tumor-infiltrating lymphocyte (TIL) status were determined. The EGFR mutation L858R-specific PNA:DNA probe detected heterogeneously localized mutations with a sensitivity similar to detection with the anti-L858R antibody. TIL analysis of L858R-mutated tumors revealed that CD8

Indexed as

Carcinoma, Non-Small-Cell LungDNA ProbesErbB ReceptorsLung NeoplasmsMutationPeptide Nucleic AcidsAgedFemaleHigh-Throughput Nucleotide SequencingHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedDNA ProbesEGFR protein, humanErbB ReceptorsPeptide Nucleic AcidsCancer genome analysisEpidermal growth factor receptor mutationNext generation sequencingPNA probeTumor-infiltrating lymphocyte (TIL)

Identifiers

PMID40175465
PMCPMC11965507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.